<DOC>
	<DOCNO>NCT00053911</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug , give surgery , may kill remain tumor cell follow surgery . It yet know whether combination chemotherapy effective observation treat relapse nonmetastatic breast cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy observation treat woman undergone surgery relapse nonmetastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Compared With Observation After Surgery Treating Women With Relapsed Nonmetastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy adjuvant cyclophosphamide , epirubicin , fluorouracil v observation , term disease-free 5-year survival , woman undergo resection relapse nonmetastatic breast cancer initial conservative surgery . - Compare overall survival woman treat regimen . - Determine tolerance woman chemotherapy regimen . - Correlate prognostic factor survival efficacy chemotherapy regimen woman . OUTLINE : This randomize , multicenter study . Patients stratify accord menopausal status participate center . Patients randomize 1 2 treatment arm . Study begin within 42 day resection recurrent disease . - Arm I : Patients receive fluorouracil IV 1 hour , epirubicin IV 1 hour , cyclophosphamide IV 1 hour day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients receive docetaxel IV 1 hour day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . - Arm II : Patients examine day 1 63 . Patients hormone receptor positive also receive one follow hormonal therapy regimen , depend menopausal status : - Oral tamoxifen daily 5 year - Oral tamoxifen daily 5 year oral luteinizing hormone-releasing hormone ( LHRH ) agonist therapy ( e.g. , goserelin ) 3 year - Oral LHRH agonist therapy ( e.g. , goserelin ) 3 year - Oral antiaromatase therapy ( e.g. , anastrozole ) 5 year Patients also undergo radiotherapy may also undergo second complete resection . Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 370 patient ( 185 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast No contralateral breast cancer Local tumor recurrence 6 month conservative surgery Complete conservative resection recurrent tumor NOTE : Initial complete surgical resection allow No local inflammatory disease disease amenable complete surgical resection No positive axillary lymph nod No distant metastasis , include subclavicular lymph node Hormone receptor status : Hormone receptor status know PATIENT CHARACTERISTICS : Age 18 65 Sex Female Menopausal status Menopausal status know Performance status ECOG 01 Life expectancy Not specify Hematopoietic Neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great upper limit normal ( ULN ) Transaminases great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN No chronic hepatitis B No active hepatitis C Renal Not specify Cardiovascular Cardiac function normal echocardiogram isotope Other No contraindication anthracyclines follow : Prior doxorubicin 300 mg/m^2 Prior epirubicin 600 mg/m^2 Prior mitoxantrone 90 mg/m^2 No invasive malignancy No chronic somatic psychiatric condition would preclude study participation No familial , social , geographic , psychological reason would preclude study participation Not pregnant Fertile patient must use effective contraception HIV negative CA 153 great 2 time ULN PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Patient CharacteristicsOther No prior neoadjuvant chemotherapy Endocrine therapy No prior neoadjuvant hormonal therapy Radiotherapy No prior neoadjuvant radiotherapy Surgery See Disease Characteristics At least 41 day since prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>